Impel Neuropharma

Impel Pharmaceuticals, Inc. operates as a clinical stage biotechnology firm that develops medical devices. It offers intranasal drug treatments for central nervous system (CNS) disorders. The firm’s product candidates include TRUDHESA, INP105, and INP107. The company was founded by Rodney J. Y. Ho, John D. Hoekman, and Michael P. Hite in 2008 and is headquartered in Seattle, WA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Ipi Legacy Liquidation Co. is a commercial-stage biopharmaceutical company. It engages in the development and commercialization of transformative therapies for patients suffering from diseases with high unmet medical needs with an initial focus on diseases of the central nervous system. The company was founded by Rodney J. Y. Ho, John D. Hoekman, and Michael P. Hite in 2008 and is headquartered in Seattle, WA.

Patient Access to Trudhesa® to Continue Uninterrupted Sufficient Liquidity to Fund Day to Day Operations During Court-Supervised Process SEATTLE , Dec. 19, 2023 /PRNewswire/ -- Impel Pharmaceuticals Inc. (OTCQX: IMPL) ("Impel" or "the Company"), a commercial-stage biopharmaceutical company with a mission to develop transformative therapies for people suffering from diseases with high unmet medical needs, today announced that it is pursuing a sale of the Company and has entered into an agreement with JN BIDCO LLC to serve as the "stalking horse" bidder to acquire the Company and its assets. To facilitate an orderly sale process, the Company has filed voluntary petitions to commence chapter 11 proceedings in the U.S. Bankruptcy Court for the Northern District of Texas (the "Court"), which will provide interested parties the opportunity to submit higher and better offers.

Impel Pharmaceuticals Announces Filing of Voluntary Chapter 11 Cases and Signing of "Stalking Horse" Agreement to Facilitate Sale

Impel Pharmaceuticals (NASDAQ: IMPL ) stock is on the rise Friday after the company announced an amended credit agreement with Oaktree Fund Administration. This new credit agreement has Impel Pharmaceuticals obtaining a loan of $121.5 million from new and existing investors.

Why Is Impel Pharmaceuticals (IMPL) Stock Up 32% Today?

Impel Pharmaceuticals (NASDAQ: IMPL ) stock is falling on Wednesday after the biopharmaceutical company failed to file its earnings report on time. According to a filing with the Securities and Exchange Commission (SEC), several issues kept Impel Pharmaceuticals from filing in a timely manner.

Why Is Impel Pharmaceuticals (IMPL) Stock Down 35% Today?

Real-World Assessment Suggests that Concomitant Preventive and Acute Medication Use Decreases in Patients Using Trudhesa

Impel Pharmaceuticals to Present New Real-World Data for Trudhesa® at the 65th Annual Scientific Meeting of the American Headache Society

Impel Pharmaceuticals Inc. (NASDAQ:IMPL ) Q1 2023 Earnings Conference Call May 12, 2023 8:30 AM ET Company Participants Adrian Adams - Chairman and Chief Executive Officer Michael Kalb - Chief Financial Officer Leonard Paolillo - Chief Commercial Officer Rajiv Amin - Controller Conference Call Participants Stacy Ku - TD Cowen Eddie Hickman - Guggenheim Securities Sean Kim - Jones Trading Operator Good morning, ladies and gentlemen and welcome to Impel Pharmaceuticals First Quarter 2023 Earnings and Business Update Conference Call. At this time, all participants are in a listen-only mode.

Impel Pharmaceuticals Inc. (IMPL) Q1 2023 Earnings Call Transcript

Trudhesa® Achieved nTRx of Over 18.5K in Q1 2023; Increase of 112% vs. Q1 2022 Trudhesa Net Product Revenue in Q1 2023 Increased 149% vs.

Impel Pharmaceuticals Announces First Quarter 2023 Financial Results and Provides Business Update

SEATTLE, May 05, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, today announced it will host a live webcast on Friday, May 12, 2023, at 8:30 a.m. ET to report its first quarter 2023 financial results and provide a business update.

Impel Pharmaceuticals to Report First Quarter 2023 Financial Results on Friday, May 12, 2023

New Analysis Indicates No Drug-Drug Interactions (DDIs) of Clinical Concern are Predicted When Recommended Doses of Trudhesa and Gepants are Co-Administered

Impel Pharmaceuticals Presents New Data at AAN 2023 Suggesting Trudhesa® Nasal Spray is Safe to Use When Co-Administered With Commonly Prescribed Migraine Medications

SEATTLE, April 12, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, today announced the appointment of Darren Cline to the Board of Directors. Mr. Cline brings more than 30 years of experience in the biopharmaceutical industry, including extensive commercialization and operational expertise.

Impel Pharmaceuticals Announces Appointment of Darren Cline to the Board of Directors

Impel Pharmaceuticals Inc. (NASDAQ:IMPL ) Q4 2022 Earnings Conference Call March 24, 2023 8:30 AM ET Company Participants Adrian Adams - Chairman & Chief Executive Officer Leonard Paolillo - Chief Commercial Officer Rajiv Amin - Controller & Interim Chief Financial Officer Conference Call Participants Stacy Ku - Cowen Eddie Hickman - Guggenheim Partners Laura Chico - Wedbush Sean Kim - JonesTrading Operator Good morning, ladies and gentlemen and welcome to Impel Pharmaceuticals Fourth Quarter and Full Year 2022 Earnings and Business Update Conference Call. [Operator Instructions] As a reminder, today's conference is being recorded.

Impel Pharmaceuticals Inc. (IMPL) Q4 2022 Earnings Call Transcript

Impel Pharmaceuticals Inc. (IMPL) delivered earnings and revenue surprises of 6.73% and 23.35%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Impel Pharmaceuticals Inc. (IMPL) Reports Q4 Loss, Tops Revenue Estimates

Trudhesa® Achieved nTRx of Over 58.4K in 2022; nTRx Increased by 19.4% in Q4 vs. Q3 2022

Impel Pharmaceuticals Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

SEATTLE, March 17, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, today announced it will host a live webcast on Friday, March 24, 2023, at 8:30 a.m. ET to report its fourth quarter and full year 2022 financial results and provide a business update.

Impel Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on Friday, March 24, 2023

SEATTLE, March 03, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, today announced that the Company will participate in two upcoming investor conferences in March:

Impel Pharmaceuticals to Participate in Upcoming Investor Conferences in March

Cost-Saving Measures Eliminate Pipeline Programs and Reduce Headcount by 16 Percent

Impel Pharmaceuticals Announces Strategic Repriortization, Continues Focus on Maximizing Trudhesa® Commercial Opportunity

Impel Pharmaceuticals Inc. (NASDAQ:IMPL ) Q3 2022 Results Conference Call November 14, 2022 8:30 AM ET Company Participants John Leaman - Chief Financial & Business Officer Adrian Adams - Chairman & CEO Leonard Paolillo - Chief Commercial Officer Conference Call Participants Ken Cacciatore - Cowen Operator Good morning, ladies and gentlemen, and welcome to Impel Pharmaceuticals Third Quarter 2022 Earnings and Business Update Conference Call. At this time, all participants are in a listen-only mode.

Impel Pharmaceuticals Inc. (IMPL) Q3 2022 Earnings Call Transcript

Impel Pharmaceuticals Inc. (IMPL) delivered earnings and revenue surprises of -50.57% and 40.27%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Impel Pharmaceuticals Inc. (IMPL) Reports Q3 Loss, Lags Revenue Estimates

Trudhesa® nTRx Increased by 27% in Q3 2022 vs. Q2 2022 to 16.7k: Net Product Revenue Increased to $3.1 Million

Impel Pharmaceuticals Announces Third Quarter 2022 Financial Results and Provides Corporate Update

SEATTLE, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, today announced that the Adrian Adams, Chairman and Chief Executive Officer, will participate in a fireside chat at the Guggenheim 4th Annual Immunology and Neurology Day on Tuesday, November 15, 2022 at 1:00 p.m. ET in New York, NY.

Impel Pharmaceuticals to Participate in Guggenheim 4th Annual Immunology and Neurology Day

Impel Pharmaceuticals Inc. (NASDAQ:IMPL ) Q2 2022 Earnings Conference Call August 15, 2022 8:30 AM ET Company Participants John Leaman - Chief Financial & Business Officer Adrian Adams - Chairman & CEO Leonard S. Paolillo - Chief Commercial Officer Conference Call Participants Ken Cacciatore - Cowen Laura Chico - Wedbush Eddie Hickman - Guggenheim Securities Operator Good morning, ladies and gentlemen and welcome to Impel Pharmaceuticals' Second Quarter 2022 Earnings and Business Update Conference Call.

Impel Pharmaceuticals, Inc. (IMPL) CEO Adrian Adams on Q2 2022 Results - Earnings Call Transcript

Impel Pharmaceuticals Inc. (IMPL) delivered earnings and revenue surprises of 3.54% and 3.05%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Impel Pharmaceuticals Inc. (IMPL) Reports Q2 Loss, Tops Revenue Estimates

Trudhesa® TRx's Grew 48% in Q2 2022 to Over 13K: Net Product Revenue Increased 59%  Over Q1 2022 to $2.8 Million

Impel Pharmaceuticals Announces Second Quarter 2022 Financial Results and Provides Corporate Update

SEATTLE, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, with an initial focus on the central nervous system, today announced that Adrian Adams, Chairman and Chief Executive Officer, and John Leaman, M.D., Chief Financial and Business Officer, will participate in a fireside chat at the 2022 Wedbush PacGrow Healthcare Conference, being held virtually on Tuesday, August 9, 2022, at 12:35 p.m. ET.

Impel Pharmaceuticals to Participate in 2022 Wedbush PacGrow Healthcare Conference

CALM 201 Study to Explore the Safety and Efficacy of Single 5mg-Dose INP105 Compared to Placebo in Quickly Reducing Agitation in Participants with ASD

Impel Pharmaceuticals Announces First Patient Dosed in Phase 2a Study Evaluating INP105 to Treat Acute Agitation in Adolescents With Autism Spectrum Disorder (ASD)

Impel Pharmaceuticals has slipped under the radar since its IPO back in April of last year. The company has made significant progress with its launch of Trudhesa. Impel continues to see Trudhesa prescription momentum increasing and is confident that it will see growth in both new and refill prescriptions.

News for Impel Neuropharma Stock (IMPL)